Wenyan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenyan Yu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Guojuan Wang
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
3 shared publicationsNaicheng Zhu
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
3 shared publicationsXiudan Chen
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
3 shared publicationsChen Zhong
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
2 shared publications- Guojuan Wang
Oncology Department, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China
2 shared publications Nanxin Li
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
2 shared publications
Latest Publications
- Open Access
- 11 January 2025
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 13
Long non-coding RNAs promote colorectal cancer development through other epigenetic modifications
Colorectal cancer is one of the most prevalent malignant tumors worldwide, and it has one of the highest rates of mortality and morbidity. Its emergence and progression are intricately linked to various genetic and epigenetic factors influencing colonic epithelial cells. Long non-coding RNAs function as crucial regulators of the epigenetic landscape, playing significant roles in the development, progression, invasion, metastasis, and drug resistance of various tumors, particularly colorectal cancer. Epigenetic modifications, such as DNA methylation, RNA methylation, and histone modification, facilitate heritable gene expression regulation without changing the underlying DNA sequence. Recent studies have increasingly highlighted the intricate interactions between lncRNAs and these epigenetic modifications in colorectal cancer, illuminating their participation in critical processes, including cell proliferation, apoptosis, invasion, and metastasis. This review concentrates on the relationship between long non-coding RNAs and several significant epigenetic modifications that drive colorectal cancer development, offering fresh insights for future research that aims at devising more effective treatment strategies.
- 11 January 2025
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 13
Open AccessLong non-coding RNAs promote colorectal cancer development through other epigenetic modifications
Colorectal cancer is one of the most prevalent malignant tumors worldwide, and it has one of the highest rates of mortality and morbidity. Its emergence and progression are intricately linked to various genetic and epigenetic factors influencing colonic epithelial cells. Long non-coding RNAs function as crucial regulators of the epigenetic landscape, playing significant roles in the development, progression, invasion, metastasis, and drug resistance of various tumors, particularly colorectal cancer. Epigenetic modifications, such as DNA methylation, RNA methylation, and histone modification, facilitate heritable gene expression regulation without changing the underlying DNA sequence. Recent studies have increasingly highlighted the intricate interactions between lncRNAs and these epigenetic modifications in colorectal cancer, illuminating their participation in critical processes, including cell proliferation, apoptosis, invasion, and metastasis. This review concentrates on the relationship between long non-coding RNAs and several significant epigenetic modifications that drive colorectal cancer development, offering fresh insights for future research that aims at devising more effective treatment strategies.
- 1 January 2025
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (10) , 4499-4515
Hexokinase 2 promotes tumor development and progression
Cancer remains a leading cause of morbidity and mortality worldwide, and the abnormal activation of glycolysis is a hallmark that enables tumor cells to adapt and sustain rapid proliferation. Beyond providing energy and biosynthetic precursors, glycolysis also supports tumor cell survival, invasion, and metastasis through multiple mechanisms. Hexokinase is a key rate-limiting enzyme in glycolysis, catalyzing the phosphorylation of glucose to glucose-6-phosphate. Among its isoforms, hexokinase 2 (HK2) exhibits particularly high enzymatic activity and substrate specificity, and it plays a central role in tumor metabolic reprogramming. Recent studies have shown that HK2 is markedly upregulated in many cancer types, where it promotes tumor initiation and progression by suppressing apoptosis and enhancing proliferation and metastasis. This review summarizes current evidence on the role of HK2 in tumor development and discusses emerging therapeutic strategies targeting HK2. By clarifying the link between HK2 and cancer, we aim to provide new insights and potential clinical applications for metabolism-based therapies.
- 1 January 2025
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (10) , 4499-4515
Hexokinase 2 promotes tumor development and progression
Cancer remains a leading cause of morbidity and mortality worldwide, and the abnormal activation of glycolysis is a hallmark that enables tumor cells to adapt and sustain rapid proliferation. Beyond providing energy and biosynthetic precursors, glycolysis also supports tumor cell survival, invasion, and metastasis through multiple mechanisms. Hexokinase is a key rate-limiting enzyme in glycolysis, catalyzing the phosphorylation of glucose to glucose-6-phosphate. Among its isoforms, hexokinase 2 (HK2) exhibits particularly high enzymatic activity and substrate specificity, and it plays a central role in tumor metabolic reprogramming. Recent studies have shown that HK2 is markedly upregulated in many cancer types, where it promotes tumor initiation and progression by suppressing apoptosis and enhancing proliferation and metastasis. This review summarizes current evidence on the role of HK2 in tumor development and discusses emerging therapeutic strategies targeting HK2. By clarifying the link between HK2 and cancer, we aim to provide new insights and potential clinical applications for metabolism-based therapies.
- Open Access
- 6 May 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 719, 150046
The mechanism and clinical application of farnesyl diphosphate farnesyltransferase 1 in cancer metabolism
- 6 May 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 719, 150046
Open AccessThe mechanism and clinical application of farnesyl diphosphate farnesyltransferase 1 in cancer metabolism
- Open Access
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Background: Colorectal cancer is a major cause of mortality among the prevalent malignant tumors of the gastrointestinal tract. Although chemotherapy is a standard treatment for colorectal cancer, its efficacy is limited by chemoresistance. Recent studies have investigated targeting tumor stem cells as a potential new therapeutic approach for addressing chemoresistance in colorectal cancer. Colorectal cancer frequently relapses, with tumor stem cells often representing one of the leading causes of treatment failure. Purpose: Understanding drug resistance in colorectal cancer stem cells is crucial for improving treatment outcomes. By focusing on developing targeted therapies that specifically address drug resistance in colorectal cancer stem cells, there is potential to make significant advancements in the treatment of colorectal cancer.This approach may lead to more effective and lasting outcomes in patients battling colorectal cancer. Research Design: In this review, a comprehensive overview of recent research on colorectal cancer stem cell treatment resistance is presented.Results: Elucidating the key underlying mechanisms. This review also highlights the potential benefits of targeted therapies in overcoming colorectal cancer resistance to treatment. Conclusions: CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.The significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs is been highlighted.
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Open AccessThe Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Background: Colorectal cancer is a major cause of mortality among the prevalent malignant tumors of the gastrointestinal tract. Although chemotherapy is a standard treatment for colorectal cancer, its efficacy is limited by chemoresistance. Recent studies have investigated targeting tumor stem cells as a potential new therapeutic approach for addressing chemoresistance in colorectal cancer. Colorectal cancer frequently relapses, with tumor stem cells often representing one of the leading causes of treatment failure. Purpose: Understanding drug resistance in colorectal cancer stem cells is crucial for improving treatment outcomes. By focusing on developing targeted therapies that specifically address drug resistance in colorectal cancer stem cells, there is potential to make significant advancements in the treatment of colorectal cancer.This approach may lead to more effective and lasting outcomes in patients battling colorectal cancer. Research Design: In this review, a comprehensive overview of recent research on colorectal cancer stem cell treatment resistance is presented.Results: Elucidating the key underlying mechanisms. This review also highlights the potential benefits of targeted therapies in overcoming colorectal cancer resistance to treatment. Conclusions: CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.The significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs is been highlighted.
- 2 November 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 32 (7) , 1114-1126
Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in the PKD1 and PKD2 genes, and it is characterized by renal cyst formation, inflammation and fibrosis. Forkhead box protein M1 (FoxM1), a transcription factor of the Forkhead box (Fox) protein super family, has been reported to promote tumor formation, inflammation and fibrosis in many organs. However, the role and mechanism of FoxM1 in regulation of ADPKD progression is still poorly understood. Here, we show that FoxM1 is an important regulator of cyst growth in ADPKD. FoxM1 is upregulated in cyst-lining epithelial cells in Pkd1 mutant mouse kidneys and human ADPKD kidneys. FoxM1 promotes cystic renal epithelial cell proliferation by increasing the expression of Akt and Stat3 and the activation of ERK and Rb. FoxM1 also regulates cystic renal epithelial cell apoptosis through NF-κB signaling pathways. In addition, FoxM1 regulates the recruitment and retention of macrophages in Pkd1 mutant mouse kidneys, a process that is associated with FoxM1-mediated upregulation of monocyte chemotactic protein 1. Targeting FoxM1 with its specific inhibitor, FDI-6, delays cyst growth in rapidly progressing and slowly progressing Pkd1 mutant mouse kidneys. This study suggests that FoxM1 is a central and upstream regulator of ADPKD pathogenesis and provides a rationale for targeting FoxM1 as a therapeutic strategy for ADPKD treatment.
- 2 November 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 32 (7) , 1114-1126
Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in the PKD1 and PKD2 genes, and it is characterized by renal cyst formation, inflammation and fibrosis. Forkhead box protein M1 (FoxM1), a transcription factor of the Forkhead box (Fox) protein super family, has been reported to promote tumor formation, inflammation and fibrosis in many organs. However, the role and mechanism of FoxM1 in regulation of ADPKD progression is still poorly understood. Here, we show that FoxM1 is an important regulator of cyst growth in ADPKD. FoxM1 is upregulated in cyst-lining epithelial cells in Pkd1 mutant mouse kidneys and human ADPKD kidneys. FoxM1 promotes cystic renal epithelial cell proliferation by increasing the expression of Akt and Stat3 and the activation of ERK and Rb. FoxM1 also regulates cystic renal epithelial cell apoptosis through NF-κB signaling pathways. In addition, FoxM1 regulates the recruitment and retention of macrophages in Pkd1 mutant mouse kidneys, a process that is associated with FoxM1-mediated upregulation of monocyte chemotactic protein 1. Targeting FoxM1 with its specific inhibitor, FDI-6, delays cyst growth in rapidly progressing and slowly progressing Pkd1 mutant mouse kidneys. This study suggests that FoxM1 is a central and upstream regulator of ADPKD pathogenesis and provides a rationale for targeting FoxM1 as a therapeutic strategy for ADPKD treatment.